ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Strike while the iron is hot, advises the old adage. Chemists in California have now taken that blacksmith’s advice to heart, using an iron catalyst to forge secondary amines from nitroarenes and olefins. The reaction provides chemists with a new tool to prepare a tough-to-synthesize set of compounds from inexpensive and abundant starting materials. It’s expected to be useful in crafting pharmaceuticals and agrochemicals.
“If you’re going to make a secondary amine, there are really just a few ways to do it,” says Phil S. Baran, an organic chemist at Scripps Research Institute, in La Jolla, Calif., who spearheaded the new reaction’s development. Chemists in Baran’s lab discovered that they could create secondary amines—even ones that are sterically hindered—by using an iron catalyst and a silane reducing agent to coordinate the coupling and reduction of a nitroarene and an olefin (Science 2015, DOI: 10.1126/science.aab0245).
Baran describes the new transformation as “reductive amination 2.0,” referring to the nearly century-old reductive amination reaction, in which a carbonyl compound is converted to an amine via reduction of an intermediate imine. Although reductive amination is a workhorse reaction for making amines, it doesn’t always do the trick. Baran’s lab reports their next-generation reductive amination often succeeds where the older reaction fails.
Baran and colleagues report 113 examples of the new transformation, including those with substrates that contain functional groups, such as alcohols and boronic acids, which wouldn’t necessarily be tolerated by other reactions that make secondary amines.
“It’s a fundamentally new way to make amines, which are arguably the most important building block used in modern medicinal chemistry,” Baran says.
To demonstrate the reaction’s utility, the chemists used it to make an intermediate en route to an HIV-1 reverse transcriptase inhibitor in a single step. A previous synthesis took three steps to make this same compound, a synthetic route that Baran estimates costs about $1,450—including materials and labor—to make 1.5 g. Baran reckons that the shortened strategy, which requires less expensive materials, would slash the synthesis cost to about $60 for 1.5 g.
“This is modern alchemy,” Baran says. “We try to take very low value starting material, and with a minimal amount of effort, convert it to a high-value product, which conceptually is identical to what alchemists were trying to do.”
The reaction is not without its limitations, Baran and colleagues point out. It doesn’t work well on nitroalkanes, for example. Also, two to three equivalents of olefin are required, which isn’t ideal if the olefin is expensive or requires a complex synthesis.
Even so, László Kürti, an organic chemistry professor at Rice University who specializes in amines and nitroarenes, thinks the transformation will be widely applicable in both academic and industrial labs. “To me, this is a really clever and effective way of getting to these complicated compounds,” Kürti says. “If you look at the substrate scope, it’s amazing. I don’t see many papers where you have over 100 examples. That is a testament to the robustness of this method.”
Baran tells C&EN that he hopes the paper’s extensive supporting information will provide chemists with all the information they need to do the reaction. He and his lab will also address questions about it on their Open Flask blog. “We really want people to be able to adopt this immediately,” Baran says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter